Duke brain cancer researcher Kyle Walsh named director of NIEHS

FDA, Telix agree on NDA resubmission pathway for TLX101-CDx, an investigational agent for glioma imaging

FDA and Telix have reached an agreement regarding resubmission of its New Drug Application for TLX101-CDx (Floretyrosine F18 or 18F-FET, Pixclara), an investigational agent for the imaging of glioma, a rare and life-threatening brain cancer.

September 19, 2025

Vol.51 No.34

Clinical Roundup

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain cancer newly sensitive to both radiation and chemotherapy drugs, and blocks the cancer’s ability to invade other tissue, a new study shows.

July 03, 2025

Vol.51 No.26

Cancer Policy

AMA President Bobby Mukkamala, brain cancer survivor, says NIH research saved his life

In November 2024, Bobby Mukkamala was giving a routine talk to a group of physicians and medical students when his language suddenly became garbled. For a minute or two, he stopped making any sense.

Diet influences survival after stage 3 colon cancer, Dana-Farber study finds

Patients with colon cancer who consumed an anti-inflammatory diet during a phase III clinical trial showed longer overall survival post-treatment, compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Study uncovers source of genetic variation influencing childhood brain tumors

Researchers at Baylor College of Medicine and collaborating institutions investigated for the first time in cancer the association between two sources of genetic variation: germline or inherited structural variation, which refers to large differences in the DNA sequence, and DNA methylation, which is when genes are turned on or off without altering the DNA code.

May 23, 2025

Vol.51 No.20

Clinical Roundup

New compound targets circadian clock machinery in cells to fight glioblastoma

A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow.

May 16, 2025

Vol.51 No.19

Duke brain cancer researcher Kyle Walsh named director of NIEHS

YOU MAY BE INTERESTED IN

FDA, Telix agree on NDA resubmission pathway for TLX101-CDx, an investigational agent for glioma imaging

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

AMA President Bobby Mukkamala, brain cancer survivor, says NIH research saved his life

Diet influences survival after stage 3 colon cancer, Dana-Farber study finds

Study uncovers source of genetic variation influencing childhood brain tumors

New compound targets circadian clock machinery in cells to fight glioblastoma

Renew today!

Subscriber content

Never miss an issue!

Login